UCB SA (OTCMKTS:UCBJF) Short Interest Down 22.6% in September

UCB SA (OTCMKTS:UCBJF) was the recipient of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 419,400 shares, a decrease of 22.6% from the September 15th total of 542,000 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is currently 4,194.0 days.

UCB Stock Performance

UCBJF opened at $179.05 on Tuesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The business has a fifty day moving average of $174.76 and a 200 day moving average of $147.76. UCB has a 52-week low of $69.70 and a 52-week high of $180.00.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.